Brokers Set Expectations for RCUS FY2025 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Arcus Biosciences in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings per share of ($5.29) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.06. The company had revenue of $48.00 million for the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm’s revenue was up 50.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.94) EPS.

Several other equities research analysts also recently issued reports on RCUS. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. HC Wainwright reiterated a “neutral” rating and issued a $20.00 target price on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Barclays boosted their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Finally, Wells Fargo & Company began coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price objective for the company. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Arcus Biosciences presently has an average rating of “Buy” and an average price target of $34.00.

Arcus Biosciences Stock Up 0.6 %

Shares of Arcus Biosciences stock opened at $14.11 on Wednesday. Arcus Biosciences has a 52 week low of $13.51 and a 52 week high of $20.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The business has a 50 day moving average price of $15.46 and a 200-day moving average price of $15.93.

Insiders Place Their Bets

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the sale, the chief financial officer now directly owns 60,138 shares in the company, valued at $902,070. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 12.30% of the company’s stock.

Institutional Trading of Arcus Biosciences

A number of institutional investors have recently modified their holdings of the business. Point72 Hong Kong Ltd bought a new position in Arcus Biosciences in the 3rd quarter worth about $47,000. Point72 DIFC Ltd bought a new position in shares of Arcus Biosciences in the second quarter valued at approximately $83,000. Quest Partners LLC boosted its position in shares of Arcus Biosciences by 40,904.3% in the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after acquiring an additional 9,408 shares during the period. Intech Investment Management LLC purchased a new position in Arcus Biosciences during the third quarter valued at approximately $244,000. Finally, Martingale Asset Management L P bought a new stake in Arcus Biosciences during the 3rd quarter worth approximately $251,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.